Ascentage Pharma Group International

As of June 30, 2026, ASCENTAGE PHARMA GROUP carries a market capitalization of 1.69B, placing it among publicly traded companies globally. Its enterprise value stands at 1.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ASCENTAGE PHARMA GROUP's next confirmed earnings release is scheduled for March 31, 2027.

As of June 30, 2026, ASCENTAGE PHARMA GROUP has 373.56M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, ASCENTAGE PHARMA GROUP maintains a current ratio of 1.22, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 13, 2026, ASCENTAGE PHARMA GROUP's stock has declined approximately 59.76% over the past 52 weeks.

As of June 30, 2026, ASCENTAGE PHARMA GROUP holds 279.39M in cash and equivalents against 308.72M in total debt, resulting in a net debt position of 25.83M. Total book value stands at 82.01M, with working capital of 60.40M providing operational flexibility.